Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 247

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 247
---
ATE & ADYNOVATE/ADYNOVI      Marketed products                           269,275      220,595      5 Years                        
  ALUNBRIG                        Marketed products                           212,376      163,329      6 Years                        
  VYVANSE/ELVANSE                 Marketed products                           223,589       95,566      1 Year                         

Impairment

Takeda’s impairment assessment for intangible assets requires a number of significant judgments to be made by management to estimate the recoverable amount, including the estimated pricing and costs, likelihood of regulatory approval, and the estimated market and Takeda’s share of the market. The most significant assumption for intangible assets associated with marketed products is the product market share of the therapeutic area and estimated pricing, whereas the most significant assumption with pre-marketed products and in-process R& D is the probability of regulatory approval. A change in these assumptions may have a significant impact on the amount, if any, of an impairment charge recorded during a period. For example, negative results from a clinical trial may change the assumption and result in an impairment. Products in development may be fully impaired when a trial is unsuccessful and there is no alternative use for the development asset.

During the year ended March 31, 2023, Takeda recorded impairment losses of JPY 57,341 20,545

During the year ended March 31, 2024, Takeda recorded impairment losses of JPY 169,405 73,979 28,477 35,686

During the year ended March 31, 2025, Takeda recorded impairment losses of JPY 95,602 163,392

These losses are recognized mainly in amortization and impairment losses on intangible assets associated with products in the consolidated statements of profit or loss.

F-40

Impairment losses were calculated by deducting the recoverable amount from the carrying amount.

For the year ended March 31, 2023, the recoverable amount was calculated at value in use and the significant assumptions used are as follows:

                                         Discount rate      Discount rate  
  For the year ended March 31, 2023      6.5% - 22.0%       8.6% - 27.5%   

For the years ended March 31, 2024 and 2025, the recoverable amount was measured at fair value less costs of disposal.